Yung‐Jue Bang

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial”.

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

Nature Medicine(2023)10.1038/s41591-023-02321-8

N/A

4.1DataRank · unranked

307 citations

Robert J. Kreitman, Zev A. Wainberg, Anas Gazzah, Ulrik Lassen, Alexander Stein +18 more

DLC-1 suppresses non-small cell lung cancer growth and invasion by RhoGAP-dependent and independent mechanisms

UNC Libraries(2020)10.17615/a4jv-yy19

N/A

0DataRank · unranked

0 citations

Savitri Maddileti, Adam Shutes, Rudolph L. Juliano, Channing J. Der, T. Kendall Harden +5 more

Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients

UNC Libraries(2020)10.17615/g9e9-qj75

N/A

0DataRank · unranked

0 citations

Ramesh K. Ramanathan, Robert P. Edwards, William C. Zamboni, Yung‐Jue Bang

Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-008339

N/A

0DataRank · unranked

53 citations

Yoon-La Choi, Taebum Lee, Hyojin Kim, Young Kwang Chae, Ben W. Dulken +25 more

Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations

European Journal of Cancer(2024)10.1016/j.ejca.2024.114024

N/A

0DataRank · unranked

26 citations

Markus Joerger, Yung‐Jue Bang, Ron H.J. Mathijssen, Caicun Zhou, Li Zhang +6 more